Histrelin Subcutaneous Implant in Children With Central Precocious Puberty
Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pre-treated or treatment naive patients with gonadotropin-dependent precocious puberty
- Pre-treatment pubertal type response of LH to a stndard GnRH stimulation test before initiation of treatment
Exclusion Criteria:
- Children who are less than 2 years of age at enrollment
- Children whose chronological age is greater than 8 years (naive) and 10 years (pre-treated) for girls or 9 years (naive) and 11 years (pre-treated) for boys at the onset of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Histrelin Subcutaneous Implant (50 mg)
Subcutaneous implant designed to deliver histrelin continously for 12 months.
|
histrelin subcutaneous 50 mg implant
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Luteinizing Hormone (LH)
Time Frame: Baseline - 6 Months Post Last Implant
|
The suppression of gonadotropins (luteinizing hormone and follicle stimulating hormone) and gonadal sex steroids (estrogen in girls and testosterone in boys, respectively) on treatment.(LH
suppression is defined as a peak LH < 4 mIU/mL following stimulation with the GnRH analog).
|
Baseline - 6 Months Post Last Implant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Follicle Stimulating Hormone (FSH)
Time Frame: Baseline - 6 Month Post Last Implant
|
The suppression of gonadotropins (luteinizing hormone and follicle stimulating hormone) and gonadal sex steroids (estrogen in girls and testosterone in boys, respectively) on treatment.(LH
suppression is defined as a peak LH < 4 mIU/mL following stimulation with the GnRH analog).
|
Baseline - 6 Month Post Last Implant
|
|
Testosterone
Time Frame: Baseline - 12 Months Post Last Implant
|
Long-term treatment with histrelin acetate suppresses the LH response to GnRH causing LH levels to decrease to prepubertal levels within 1 month of treatment.
As a result, serum concentrations of sex steroids (estrogen or testosterone) also decrease.
Testosterone suppression is defined as serum testosterone < 30.0 ng/dL (0.8 nmol/L) in boys following the induction of suppression.
One black female participant age 8.9 years old had a testosterone value of 11ng/dL at visit 4 (month 6).
|
Baseline - 12 Months Post Last Implant
|
|
DHEA Sulfate
Time Frame: Baseline - 36 Months Post Last Implant
|
DHEA=Dehydroepiandrosterone
|
Baseline - 36 Months Post Last Implant
|
|
Estradiol (MS)
Time Frame: Month 36 - 36 Months Post Last Implant
|
Long-term treatment with histrelin acetate suppresses the LH response to GnRH causing LH levels to decrease to prepubertal levels within 1 month of treatment.
As a result, serum concentrations of sex steroids (estrogen or testosterone) also decrease.
Estradiol suppression is defined as serum estradiol in the assay specific range < 20 pg/mL (73 pmol/L) in girls following the induction of suppression.
|
Month 36 - 36 Months Post Last Implant
|
|
Estradiol (RIA)
Time Frame: Baseline - Month 24
|
Long-term treatment with histrelin acetate suppresses the LH response to GnRH causing LH levels to decrease to prepubertal levels within 1 month of treatment.
As a result, serum concentrations of sex steroids (estrogen or testosterone) also decrease.
Estradiol suppression is defined as serum estradiol in the assay specific range < 20 pg/mL (73 pmol/L) in girls following the induction of suppression.
|
Baseline - Month 24
|
|
Average Number of Implants Received
Time Frame: 12 months
|
There were 2 implants received that were not removed during the study and were excluded from this analysis due to unknown duration of treatment.
|
12 months
|
|
Average Mean Implant Duration by Subject
Time Frame: 12 Months
|
There were 2 implants received that were not removed during the study and were excluded from this analysis due to unknown duration of treatment.
|
12 Months
|
|
Summary of EN3326 Implantation and Explantations
Time Frame: Day 1 - Month 60
|
Once the female participants reached 11 years of age and the male participants reached 12 years of age or the investigator determined that subjects no longer required hormone suppression, participants underwent final explantation and were eligible to continue into an optional Long Term Follow Up Phase (Post Implant Treatment Phase) for up to 5 years.
The purpose of the optional Long Term Follow Up Phase was to collect additional medical and developmental information, such as onset of menses and final adult height after hormone suppression was discontinued.
|
Day 1 - Month 60
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erica A Eugster, MD, Indiana University School of Medicine, 705 Riley Hosp Dr, Rm 5960 Indianapolis, IN 46202
Publications and helpful links
General Publications
- Silverman LA, Neely EK, Kletter GB, Lewis K, Chitra S, Terleckyj O, Eugster EA. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial. J Clin Endocrinol Metab. 2015 Jun;100(6):2354-63. doi: 10.1210/jc.2014-3031. Epub 2015 Mar 24.
- Neely EK, Silverman LA, Geffner ME, Danoff TM, Gould E, Thornton PS. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol. 2013 Dec 2;2013(1):20. doi: 10.1186/1687-9856-2013-20.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EN3326-300Former03-CPP-HIS-300
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.